RT Book, Section
T1 Clinical Trials Involving Chemotherapy-Based Nanocarriers in Cancer Therapy: State of the Art and Future Directions
A1 Lopez Mendez, Tania B.
A1 Strippoli, Raffaele
A1 Trionfetti, Flavia
A1 Calvo, Pilar
A1 Cordani, Marco
A1 Gonzalez-Valdivieso, Juan
A2 Almeida de Sousa, Ângela Maria
A2 Pienna Soares, Christiane Pienna Soares
A2 Chorilli, Marlus
AB Despite significant achievements in cancer treatment, it remains a challenging burden, and there is limited success in the clinical therapy. In recent years, progress in nanotechnology provides plenty of tools to counteract cancer with innovative nanomedicines that can be exploited in intracellular drug delivery. Specifically, the design and development of nanomaterials, such as nanoparticles and hydrogels, aim at achieving smart nanosystems with great multifunctionality and therapeutic potential. In this context, advances in tailored biomaterials for drug delivery as cancer treatment include new strategies to overcome the obstacles and limitations usually encountered with traditional therapeutic agents, thereby reducing the lack of selectivity and side effects. Hence, a big effort is being invested in designing and developing more accurate strategies toward personalized medicine, which has emerged as a promising therapeutic approach with a wide potential to increase treatment outcomes and patient survival. In this chapter, we provide a comprehensive analysis and discuss the development of advanced nanocarriers involving chemotherapeutic agents in clinical trials against multiple types of cancer. We also focus on some reasons that could explain why some treatments fail in clinics.
PB SPRINGER NATURE
SN 978-3-031-17830-6
YR 2022
FD 2022
LK https://hdl.handle.net/20.500.14352/2500
UL https://hdl.handle.net/20.500.14352/2500
LA eng
NO Maria Zambrano Contract
NO Ministerio de Universidades
NO Universidad Complutense de Madrid
DS Docta Complutense
RD 15 may 2024